NCT02773459View on ClinicalTrials.gov

MEK162 in Combination With Capecitabine in Advanced Biliary Tract Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

January 7, 2019

Study Completion Date

January 7, 2019

Conditions
Biliary Tract Cancer
Interventions
DRUG

MEK162+capecitabine

In phase 1 part: capecitabine(mg/m2) will be given twice a day, 2 week on/1week off Q 3weeks + MEK162 twice a day, continuously, starting at 1000mg/m2 and 30mg/m2 respectively. Expansion part will be treated with the dose found at phase 1 part.

Trial Locations (1)

110-744

Seoul National University Hospital, Seoul

All Listed Sponsors
lead

Seoul National University Hospital

OTHER

NCT02773459 - MEK162 in Combination With Capecitabine in Advanced Biliary Tract Cancer | Biotech Hunter | Biotech Hunter